Recent Company News

• 06:10 PM ET Oct 20, 2025
  

  Sino Biopharmaceutical reports interim analysis results of Phase III clinical study (CULMINATE-2) of culmerciclib presented at ESMO (HK$7.43, 0.00)

• 06:34 AM ET Oct 15, 2025
  

  NMPA includes Sino Biopharmaceutical's TQ-B3234 in breakthrough therapy designation process for plexiform neurofibromas associated with NF1 (HK$7.51, 0.00)

• 07:41 AM ET Oct 13, 2025
  

  Sino Biopharmaceutical's TQB2102 "HER2 bispecific ADC" included in NMPA Breakthrough Therapeutic Designation process (HK$7.80, 0.00)

• 11:53 PM ET Oct 08, 2025
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 03:23 AM ET Oct 06, 2025
  

  StreetAccount Sector Summary - China Healthcare September Recap

• 12:50 PM ET Sep 26, 2025
  

  White House says the latest pharmaceutical tariffs do not apply to countries with negotiated trade deals -- wires

• 08:15 PM ET Sep 25, 2025
  

  Trump says pharmaceutical products imported into US will be hit with 100% tariff starting 1-Oct - Truth Social post

• 06:24 AM ET Sep 25, 2025
  

  Sino Biopharmaceutical completes first patient enrollment for LM-350 CDH17 ADC phase I trial in Australia (HK$8.01, 0.00)

• 04:49 AM ET Sep 23, 2025
  

  Sino Biopharmaceutical completes first patient enrollment for phase I clinical trial for LM-2417 in China (HK$8.14, 0.00)

• 11:49 PM ET Sep 22, 2025
  

  Sino Biopharmaceutical initiated buy at Sinolink Securities (22-Sep, timing uncertain) (HK$8.08, -0.44)